385 related articles for article (PubMed ID: 30848394)
1. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Huang LW; Wong SW; Andreadis C; Olin RL
Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for hematologic malignancies.
Kuriakose P
Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
[TBL] [Abstract][Full Text] [Related]
3. [Hematological malignancies].
Usui N
Gan To Kagaku Ryoho; 2007 Mar; 34(3):358-66. PubMed ID: 17353625
[TBL] [Abstract][Full Text] [Related]
4. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia.
Fattizzo B; Radice T; Cattaneo D; Pomati M; Barcellini W; Iurlo A
Clin Lab; 2014; 60(11):1929-32. PubMed ID: 25648037
[TBL] [Abstract][Full Text] [Related]
5. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
6. Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies.
Leśniak M; Lipniarska J; Majka P; Lejman M; Zawitkowska J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069030
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
[TBL] [Abstract][Full Text] [Related]
8. Individualizing treatment decisions for older adults with hematologic malignancies.
Klepin HD; Rizzieri D; Palumbo A; Magarotto V; Eichhorst B
Am Soc Clin Oncol Educ Book; 2013; ():208-19. PubMed ID: 23714504
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in chronic lymphocytic leukemia.
Ferrajoli A; Faderl S; Keating MJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
[TBL] [Abstract][Full Text] [Related]
10. Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.
Knepper TC; Saller J; Walko CM
Oncology (Williston Park); 2017 Feb; 31(2):138-46. PubMed ID: 28205194
[TBL] [Abstract][Full Text] [Related]
11. B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management.
Rogers BB
Clin J Oncol Nurs; 2020 Apr; 24(2):199-204. PubMed ID: 32196006
[TBL] [Abstract][Full Text] [Related]
12. Integrating New Therapies for Chronic Lymphocytic Leukemia.
Burger JA
Cancer J; 2021 Jul-Aug 01; 27(4):275-285. PubMed ID: 34398554
[TBL] [Abstract][Full Text] [Related]
13. Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.
Jain N; Thompson P; Ferrajoli A; Nabhan C; Mato AR; O'Brien S
Am Soc Clin Oncol Educ Book; 2018 May; 38():580-591. PubMed ID: 30231393
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults.
Huang LW; Olin RL
J Geriatr Oncol; 2017 Nov; 8(6):417-420. PubMed ID: 28835351
[TBL] [Abstract][Full Text] [Related]
15. The 50th Annual Meeting of the American Society of Hematology.
Cunningham S; Muneer S
Clin Lymphoma Myeloma; 2009 Jun; 9(3):197-205. PubMed ID: 19525188
[No Abstract] [Full Text] [Related]
16. Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies.
Crassini K; Gibson J
Intern Med J; 2024 Jan; 54(1):16-25. PubMed ID: 38066723
[TBL] [Abstract][Full Text] [Related]
17. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.
Kim SY; Theunissen JW; Balibalos J; Liao-Chan S; Babcock MC; Wong T; Cairns B; Gonzalez D; van der Horst EH; Perez M; Levashova Z; Chinn L; D'Alessio JA; Flory M; Bermudez A; Jackson DY; Ha E; Monteon J; Bruhns MF; Chen G; Migone TS
Blood Cancer J; 2015 May; 5(5):e316. PubMed ID: 26024286
[TBL] [Abstract][Full Text] [Related]
18. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
[TBL] [Abstract][Full Text] [Related]
20. Targeting MCL1, Companies Aim to Unblock Apoptosis.
Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
